From Discovery To Development To Delivery

AZBio is committed to building a top-tier life science industry in Arizona.

Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)

IN THE LOOP

AZBio In The Loop is your opportunity to stay up to date on what is happening across Arizona's Life Science and Healthcare Community.

Subscribe

AZBio Members Are Making LIFE Bettter

AZBio Members discover, develop, and deliver life-saving and life-changing innovations.

Premiere Supporters

Leadership Supporters

Sustaining Members

Get Connected With Arizona's Bioindustry

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry.  AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.

 

Success Stories – Good News from Arizona’s BioIndustry

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals Inc., combination therapy offers the potential of a safer and more effective approach to a wide variety of cancer treatments

Oncology Pharma is pleased to announce that Kalos Therapeutics’ lead compound, KTH-222, can produce a reduction in the attachment of newly seeded cells to a solid-phase by an average of 39%. These non-clinical results suggest that KTH-222 disrupt tubulin formation and attachment to the solid-phase in a similar way to most of the commonly used […]

Discovery may expand cancer vaccine capabilities

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University’s Biodesign Institute have pooled their energies into an often scoffed-at, high-risk, high-reward goal in medicine: to develop a universal vaccine to prevent cancer.

AZBio Builds Relationships With Partners Across The Country

Partner Opportunities for AZBio Members

  • Click the image to learn more - Join us on October 2, 2019